Table 2.
Progression‐free survival (PFS) treatment effect in patients with advanced, progressive, well‐differentiated, non‐functional lung neuroendocrine tumors treated with everolimus or placebo, based on central radiology review, grouped by prior therapies
| Prior therapy | Median PFS, months (95% CI) | |
|---|---|---|
| Everolimus (n = 63) | Placebo (n = 27) | |
| Overall lung subgroup (n = 90) | 9.2 (6.8‐10.9) | 3.6 (1.9‐5.1) |
| Prior chemotherapy (n = 38) | 8.5 (5.6‐11.7) | 2.9 (1.8‐3.7) |
| No prior chemotherapy (n = 52) | 9.2 (6.0‐NE) | 3.7 (1.7‐NE) |
| Prior SSA (n = 38) | 9.5 (6.0‐11.7) | 3.7 (1.0‐11.2) |
| No prior SSA (n = 52) | 9.2 (5.6‐11.0) | 3.6 (1.9‐5.6) |
| Prior radiotherapya (n = 38) | 9.2 (5.7‐NE) | 3.0 (1.9‐5.1) |
| No prior radiotherapy (n = 52) | 9.2 (6.0‐9.9) | 3.7 (1.7‐NE) |
| Any prior therapy (n = 78) | 9.2 (6.0‐11.0) | 3.4 (1.9‐5.1) |
| No prior therapy (n = 12) | 9.7 (0.9‐NE) | 3.6 (1.7‐NE) |
CI, confidence interval; NE, not evaluable; SSA, somatostatin analog.
a
Includes peptide receptor radionuclide therapy.